The GLP-1 analog semaglutide demonstrated a strong ability to resolve NASH, and is associated with weight loss and improved cardiovascular health, but did not statistically significantly improve fibrosis (326). Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.